U.S. Pharmaceuticals & Biotech Most Popular Stocks

CEL-SCI

Market Cap: US$68.0m

A clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.

BeyondSpring

Market Cap: US$67.8m

A clinical stage biopharmaceutical company, focuses on the development of cancer therapies.

OS Therapies

Market Cap: US$66.8m

A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

Arch Biopartners

Market Cap: US$66.8m

Engages in the development of novel drugs for acute kidney injury and organ damage in Canada.

Immix Biopharma

Market Cap: US$66.6m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

Unicycive Therapeutics

Market Cap: US$66.1m

A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.

Adlai Nortye

Market Cap: US$65.7m

A clinical-stage biotechnology company, engages in the research and development of pharmaceutical products.

Jasper Therapeutics

Market Cap: US$65.1m

A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.

Gain Therapeutics

Market Cap: US$62.2m

A biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.

MiNK Therapeutics

Market Cap: US$61.6m

A clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.

MediciNova

Market Cap: US$60.8m

A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

Camp4 Therapeutics

Market Cap: US$60.5m

A clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.

Clene

Market Cap: US$59.2m

A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

Precision BioSciences

Market Cap: US$58.1m

A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.

Karyopharm Therapeutics

Market Cap: US$57.8m

A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

Aligos Therapeutics

Market Cap: US$57.6m

A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.

Vicapsys Life Sciences

Market Cap: US$57.3m

Focuses on the development and commercialization of VICAPSYN, a proprietary product.

Genenta Science

Market Cap: US$57.2m

A clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.

Growth Stalk Holdings

Market Cap: US$57.1m

Engages in the sowing of the seeds for cultivation and selling of cannabis.

Plus Therapeutics

Market Cap: US$55.9m

A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.

Incannex Healthcare

Market Cap: US$55.7m

A clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia.

BioXcel Therapeutics

Market Cap: US$55.4m

Together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.

Relmada Therapeutics

Market Cap: US$55.1m

Operates as a clinical-stage biotechnology company in the United States.

MariMed

Market Cap: US$55.1m

Engages in cultivation, production, and selling of branded cannabis products in the United States and internationally.

ImmuCell

Market Cap: US$54.7m

An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.

Celularity

Market Cap: US$54.5m

A regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases.

INmune Bio

Market Cap: US$54.0m

A clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.

Odonate

Market Cap: US$53.3m

A pharmaceutical company, develops therapeutics for the treatment of cancer.

Cue Biopharma

Market Cap: US$53.0m

A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.

PolyPid

Market Cap: US$52.8m

A clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.

Veru

Market Cap: US$52.6m

A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).

MAIA Biotechnology

Market Cap: US$51.8m

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.

Earth Science Tech

Market Cap: US$51.2m

Together with its subsidies, focuses on health and wellness industry.

Serina Therapeutics

Market Cap: US$51.0m

A biotechnology company, develops drugs to treat neurological diseases and pain.

ACC Aviation Holdings

Market Cap: US$49.9m

Focuses on developing canna powder products.

Actinium Pharmaceuticals

Market Cap: US$49.6m

Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.